Trust Co. of Toledo NA OH decreased its position in shares of Abbott Laboratories (NYSE:ABT) by 0.4% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 84,124 shares of the healthcare product maker’s stock after selling 309 shares during the quarter. Abbott Laboratories makes up about 1.8% of Trust Co. of Toledo NA OH’s holdings, making the stock its 8th largest position. Trust Co. of Toledo NA OH’s holdings in Abbott Laboratories were worth $10,081,000 at the end of the most recent reporting period.
Several other hedge funds have also recently modified their holdings of ABT. Atlas Private Wealth Advisors grew its holdings in shares of Abbott Laboratories by 107.3% during the fourth quarter. Atlas Private Wealth Advisors now owns 228 shares of the healthcare product maker’s stock worth $25,000 after purchasing an additional 118 shares during the last quarter. Inspire Advisors LLC acquired a new stake in shares of Abbott Laboratories during the fourth quarter worth about $29,000. Black Swift Group LLC acquired a new stake in shares of Abbott Laboratories during the fourth quarter worth about $35,000. Krane Funds Advisors LLC acquired a new stake in shares of Abbott Laboratories during the fourth quarter worth about $39,000. Finally, PrairieView Partners LLC acquired a new stake in shares of Abbott Laboratories during the fourth quarter worth about $41,000. 72.58% of the stock is currently owned by institutional investors.
Shares of ABT traded up $0.35 during mid-day trading on Thursday, reaching $120.46. The company had a trading volume of 45,349 shares, compared to its average volume of 5,249,639. The stock has a market cap of $213.40 billion, a price-to-earnings ratio of 63.55, a price-to-earnings-growth ratio of 2.06 and a beta of 0.83. The firm has a fifty day simple moving average of $119.99 and a 200-day simple moving average of $113.19. Abbott Laboratories has a fifty-two week low of $81.05 and a fifty-two week high of $128.54. The company has a current ratio of 1.70, a quick ratio of 1.19 and a debt-to-equity ratio of 0.58.
The firm also recently announced a quarterly dividend, which will be paid on Monday, May 17th. Investors of record on Thursday, April 15th will be issued a dividend of $0.45 per share. The ex-dividend date is Wednesday, April 14th. This represents a $1.80 annualized dividend and a dividend yield of 1.49%. Abbott Laboratories’s payout ratio is 55.56%.
In other news, EVP Mary K. Moreland sold 505 shares of the business’s stock in a transaction dated Tuesday, February 16th. The shares were sold at an average price of $128.49, for a total value of $64,887.45. Following the completion of the sale, the executive vice president now owns 63,878 shares of the company’s stock, valued at approximately $8,207,684.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Mary K. Moreland sold 400 shares of the business’s stock in a transaction dated Monday, February 22nd. The stock was sold at an average price of $121.84, for a total transaction of $48,736.00. Following the completion of the sale, the executive vice president now directly owns 76,886 shares of the company’s stock, valued at approximately $9,367,790.24. The disclosure for this sale can be found here. Insiders have sold a total of 27,476 shares of company stock worth $3,366,543 in the last 90 days. Company insiders own 1.70% of the company’s stock.
Several equities research analysts have recently weighed in on ABT shares. Zacks Investment Research upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $130.00 target price for the company in a research note on Tuesday, February 2nd. Raymond James raised their price objective on shares of Abbott Laboratories from $126.00 to $130.00 and gave the company an “outperform” rating in a research report on Wednesday, March 17th. SVB Leerink lifted their price target on shares of Abbott Laboratories from $115.00 to $128.00 and gave the company a “market perform” rating in a research report on Thursday, January 28th. Credit Suisse Group lifted their price target on shares of Abbott Laboratories from $118.00 to $130.00 and gave the company an “outperform” rating in a research report on Thursday, January 28th. Finally, Morgan Stanley raised their price objective on shares of Abbott Laboratories from $126.00 to $136.00 and gave the stock an “overweight” rating in a research note on Thursday, January 28th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and sixteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $122.47.
About Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, MÃ©niÃ¨re's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Featured Story: Should You Consider an Index Fund?
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.